anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adolescent major depressive disorder (MDD) is common and debilitating. Presently, gold-standard treatments are only effective for approximately half of patients, underscoring the need to develop novel interventions, particularly to target core underlying mechanisms and more effectively treat this recurrent disorder.

Rumination, the tendency to perseverate about depressive symptoms, contributes to MDD onset and predicts treatment non-response and relapse. At the neural level, rumination is characterized by elevated functional connectivity within the default mode network (DMN), and similarly, prior research has consistently demonstrated patterns of DMN hyper-connectivity in MDD. Interestingly, mindfulness meditation, which trains attentional focus to the present moment, reduces perseverative thinking, ruminative tendencies, and depression symptoms. Further, our research and others have shown that adolescents can apply mindfulness practices to decrease perceived stress, increase sustained attention, and suppress DMN activity. Although mindfulness has profound mental health benefits, for some, mindfulness alone may not be sufficient to mitigate ruminative tendencies during a depressive episode. That is, MDD symptoms, including reduced motivation, inattention, and lack of self-efficacy, may impede a patient's progress in successfully acquiring and utilizing mindfulness strategies necessary to change perceptions about one's environment and relationships. To directly address this challenge, this project will use real-time fMRI neurofeedback to enhance the acquisition and utilization of mindfulness skills to better target DMN hyper-connectivity, rumination, and depressive symptoms.

Specifically, a novel, mindfulness-based, real-time neurofeedback (mbNF) paradigm will be used whereby people observe a visual display of their brain activity and practice mindfulness to volitionally reduce DMN activation. Adolescents (N=90; ages 13-18 years) diagnosed with MDD will complete a \~45-minute mindfulness training outside the MRI scanner. To test target engagement of reducing DMN hyper-connectivity and dosing effects, adolescents will all receive mbNF and changes in brain connectivity will be examined (primary outcome). To examine dosing effects, adolescents will be randomized to receive either a 15- or a 30-minute mbNF session (n=45/dose group). Clinician-administered instruments, self-reports, and smartphone ecological momentary assessment will be used test whether mbNF contributes to a greater reduction in clinician assessed depression symptoms as well as decreased rumination post-treatment (secondary outcomes). As a whole, mbNF is directly in line with precision medicine initiatives, and if successful, could revolutionize clinical care for depressed adolescents.
The invention discloses a microcapsule prepared based on an interfacial polycondensation method and a preparation method thereof, and relates to the field of microcapsules and the preparation method thereof. The preparation method disclosed by the invention is used for solving the problem that microcapsules of slightly soluble solid medicines cannot be prepared by current interfacial polycondensation method. The microcapsule prepared based on the interfacial polycondensation method is prepared through the interfacial polycondensation method. The preparation method comprises the following steps of: 1, preparing a sodium alginate aqueous liquid; 2, preparing a liquid I; 3, preparing a liquid III; 4, spraying the liquid I to the liquid II, and filtering to obtain sodium alginate microspherical filter cakes; and 5, preparing the capsule by nterfacial polycondensation. According to the microcapsule prepared based on an interfacial polycondensation method provided by the invention, slightly soluble solid medicines can be wrapped, and the preparation process is simple and low in cost. The capsule prepared is good in controlled release effect, and the sustainable release time reaches over 3 months. The microcapsule provided by the invention is suitable for the field of pesticide and medicine slow release.
To assess the image quality parameters of dual-energy computed tomography angiography (DECTA) 40-, and 60 keV virtual monoenergetic images (VMIs) combined with deep learning-based image reconstruction model (DLM) and iterative reconstructions (IR). CT scans of 28 post EVAR patients were enrolled. The 60 s delayed phase of DECTA was evaluated. Objective [noise, contrast-to-noise ratio (CNR), signal-to-noise ratio (SNR)] and subjective (overall image quality and endoleak conspicuity - 3 blinded readers assessment) image quality analyses were performed. The following reconstructions were evaluated: VMI 40, 60 keV VMI; IR VMI 40, 60 keV; DLM VMI 40, 60 keV. The noise level of the DLM VMI images was approximately 50% lower than that of VMI reconstruction. The highest CNR and SNR values were measured in VMI DLM images. The mean CNR in endoleak in 40 keV was accounted for as 1.83 ± 1.2; 2.07 ± 2.02; 3.6 ± 3.26 in VMI, VMI IR, and VMI DLM, respectively. The DLM algorithm significantly reduced noise and increased lesion conspicuity, resulting in higher objective and subjective image quality compared to other reconstruction techniques. The application of DLM algorithms to low-energy VMIs significantly enhances the diagnostic value of DECTA in evaluating endoleaks. DLM reconstructions surpass traditional VMIs and IR in terms of image quality.
Macrophage polarization is a critical process that regulates in inflammation, pathogen defense, and tissue repair. Here we demonstrate that MST1/2, a core kinase of Hippo pathway and a recently identified regulator of inflammation, plays a significant role in promoting M2 polarization. We provide evidence that inhibition of MST1/2, achieved through either gene-knockout or pharmacological treatment, leads to increased M1 polarization in a YAP-dependent manner, resulting in the development of M1-associated inflammatory disorders. Moreover, MST1/2 inhibition also leads to a substantial reduction in M2 polarization, but this occurs through the STAT6 and MEK/ERK signaling. The STAT6 is independent of YAP, but MEK/ERK is dependent of YAP. Consistent with these observations, both MST1/2-conditional knockout mice and wild-type mice treated with XMU-MP-1, a chemical inhibitor of MST1/2, exhibited reduced M2-related renal fibrosis, while simultaneously displaying enhanced LPS-mediated inflammation and improved clearance of MCR3-modified gram-negative bacteria. These findings uncover a novel role of MST1/2 in regulating macrophage polarization and establish it as a potential therapeutic target for the treatment of macrophage-related fibrotic diseases.
Matching placebo will be administered to participants twice daily (BID) until week 16. After week 16, Apremilast will be administered to participants BID.
A new ophthalmological contact gel is highly viscous, optically transparent and does not irritate the mucous membranes of the eye. USE/ADVANTAGE - The gel can be used in vitrecomy. The contact gel (2) is placed on the cornea (7) so that the contact lens (1) can be placed on top without damaging (e.g. scratching) the corneal epithelium. The contact lens is thus situated in labile equilibrium on the cornea, swimming in the contact gel. During operation the new gel inhibits the normally frequent slipping of the contact lens. The optical image formation inside the eye is not clouded with air or blood collecting under the contact lens. Unlike in previous cases. The gel can also be used with three mirror contact glass according to Goldmann and in echography, eliminating air between the ultrasound head and the eye which would alter the sound waves. Investigations do not need to be interrupted by topping up of the gel to replace gel which has flowed away.       In an example, powdered hydroxy propyl cellulose, e.g. Methocel E4M Premium was dissolved in 0.9% saline, filtered (e.g. over a G2 frit) to a concn. of 3%, filled (e.g. into plastic syringes) and finally sterilised. (Dwg.0/3)
In the present study we utilized the "Ultreya" dataset. The Ultreya study is an online longitudinal study aimed at evaluating the effects of the pilgrimage on the Way of Saint James on mental health and wellbeing (www.estudiocamino.org). This pilgrimage involves hundreds of paths around Europe with a common termination at Santiago de Compostela (Spain), and it was one of the most important Christian pilgrimages during the Middle Ages. Currently, it is walked by thousands of people (\>300,000 per year).
INTRODUCTION: We present a unique case of monozygotic female twins with virtually identical clinical and radiological presentations of supratentorial hydrocephalus and cystic formations from the suprasellar cistern.
DISCUSSION: Evaluating genetic predispositions and prenatal exposures is crucial for hydrocephalus in twins. Familial cases imply a genetic contribution to the development of these anomalies, including chromosomal abnormalities and specific variants linked to arachnoid cyst formation in various syndromes. Extensive genetic analyses found no pathogenic variants in the twins. Prenatal exposure to anti-epileptic medication was known during pregnancy and may be associated with fetal abnormalities, but not central nervous system (CNS) malformations, and was therefore not considered the cause of the condition in the twins. The twins presenting simultaneously with hydrocephalus caused by suprasellar cysts (SAC) underwent a two-step surgical management: initial ventriculoperitoneal shunt (VPS) placement followed by fenestration. Postoperative imaging showed cyst reduction, but a secondary VPS was necessary in both cases.
CONCLUSION: Genetic analysis is less likely to identify a monogenic etiology in non-syndromic cases of SACs, which are assumed to be multifactorial. There is no established evidence linking a teratogenic effect of anti-epileptic drugs to CNS malformations. Moreover, the surgical treatment of this complex condition constitutes a point of discussion.
Acetazolamide or vasodilatory challenge should identify subjects having a abnormal cerebrovascular reactivity capacity. More specifically, after receiving the drug there will not be the expected increase in cerebral blood flow (CBF) in some of the subjects because they are already suffering from a disturbance in the vasculature's ability to respond to the signal for vasodilation. The investigators believe the presence of this deficit will be helpful in identifying patients who are at risk for potential brain ischemia due to this decreased capacity to autoregulate if/when clinically significant vasospasm occurs. The investigators predict that acetazolamide-activated regional cerebral blood flow studies will be more sensitive in the detection of mild cerebral vasospasm and will not just detect changes in cerebral blood flow as does standard perfusion imaging, but will provide information regarding changes in cerebrovascular reactivity. Under these circumstances, a better predictor of those patients at risk of cerebral infarction due to delayed vasospasm would be delineated. Identifying this "high-risk cohort" prior to the onset of clinically apparent symptoms would result in the institution of preventative measures such as triple H therapy.

The objective of this proposal is to conduct a feasibility study of acetazolamide activated C-arm cone beam CT perfusion (CBCTP) to determine its application in the prediction of symptomatic cerebral vasospasm (i.e. ischemia or stroke) in patients with aneurysmal subarachnoid hemorrhage. The initial plan is to obtain C-arm CBCTP pre- and post-intravenous infusion of 1g acetazolamide within 24 hours of symptom onset in aneurysmal subarachnoid hemorrhage patients. The hypothesis is that some of these patients that will later develop clinical vasospasm of a degree sufficient to cause cerebral ischemia. The investigators believe this cohort of patients will demonstrate altered cerebrovascular reactivity during the acetazolamide challenge at a time before there is either angiographic evidence of vasospasm or clinical evidence of abnormal perfusion.
In order to produce the health-promoting composition, lemons are cut into slices and these slices are left for 12 to 16 days at room temperature inside a container provided with a cover. After this period, approximately 1 kg of honey is poured over the lemon slices and the mixture is left inside the container for another 12 to 16 days. Afterwards, 90 to 100 g of flower pollen and 400 to 600 ml of carob syrup are added. The entire mixture is then left inside the container for an additional 9 to 11 days. Over the entire course of production, the mixture is briefly stirred once every two days. Following the 9 to 11 days, the mixture is pressed through a sieve and filtered in order to produce the finished product. The invention also relates to a composition produced according to said method.
Participants will receive cefiderocol administered via IV every 8 hours on Day 1 and continuing for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg of cefiderocol and participants ≥34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.
Patients will be join home based exercises two days a week during 12 sessions .we will prepare for the lower and upper extremity features similar to Nintendo Wii Fit exercises 30 minutes of video game exercise practices, 5 minutes warm-up exercises, 5 minutes cooling exercises and complete the 50-minute training session with the breathing exercises we will teach them. In addition to exercise sessions, patients will record their activities (walking, cycling, swimming ına) in daily life schedules with their pedometers. Thus, changes in physical activity levels will be monitored.
Akt inhibitor MK2206 will be taken PO once a week for four weeks (one cycle). Treatment will continue for as long as a subject is benefiting from the study drug.
Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
As with other drugs that antagonize dopamine D2 receptors, olanzapine, a component of LYBALVI, elevates prolactin levels, and the elevation can persist during chronic administration. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects. 

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of these drugs is considered in a patient with previously-detected breast cancer. As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in the olanzapine carcinogenicity studies conducted in mice and rats [see Nonclinical Toxicology (13.1)]. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive. 

In the 4-week placebo-controlled trial, shifts from normal to high prolactin values (>30 ng/mL for females; >20 ng/mL for males) occurred in 41.4% of females and 32.9% of males treated with LYBALVI, in 56.1% of females and 37.1% of males treated with olanzapine, and in 10% of females and 4.8% of males treated with placebo [see Use in Specific Populations (8.3)]. 

In the 24-week, olanzapine-controlled study, shifts from normal to high prolactin values occurred in 32.9% of females and 22.5% of males treated with LYBALVI, and in 41.7% of females and 28.5% of males treated with olanzapine.
The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
INTRODUCTION: There is currently no guidance on how to assess the calibration of multistate models used for risk prediction. We introduce several techniques that can be used to produce calibration plots for the transition probabilities of a multistate model, before assessing their performance in the presence of random and independent censoring through a simulation.
METHODS: We studied pseudo-values based on the Aalen-Johansen estimator, binary logistic regression with inverse probability of censoring weights (BLR-IPCW), and multinomial logistic regression with inverse probability of censoring weights (MLR-IPCW). The MLR-IPCW approach results in a calibration scatter plot, providing extra insight about the calibration. We simulated data with varying levels of censoring and evaluated the ability of each method to estimate the calibration curve for a set of predicted transition probabilities. We also developed evaluated the calibration of a model predicting the incidence of cardiovascular disease, type 2 diabetes and chronic kidney disease among a cohort of patients derived from linked primary and secondary healthcare records.
RESULTS: The pseudo-value, BLR-IPCW, and MLR-IPCW approaches give unbiased estimates of the calibration curves under random censoring. These methods remained predominately unbiased in the presence of independent censoring, even if the censoring mechanism was strongly associated with the outcome, with bias concentrated in low-density regions of predicted transition probability.
CONCLUSIONS: We recommend implementing either the pseudo-value or BLR-IPCW approaches to produce a calibration curve, combined with the MLR-IPCW approach to produce a calibration scatter plot. The methods have been incorporated into the "calibmsm" R package available on CRAN.
The invention is a female external disinfectant medicament. The components contain the following mian raw materials according to weight percent, and the raw materials are prepared into medicament: hydroxybenzoate ester 2-40%, mandelic acid 3-50%, lacidophihin 10-55% and oligose 8-50%. It is a new compound disinfectant medicament, its antibacterial effect mainly inhibiting the activity of the inner aspiratory enzyme of microbe cell and the electronic transfer enzyme system, and has the effect of destroying the permeation of microbe cell film, its antibacterial character: it has strong action on mildew and yeast mushroom. The mandelic acid has very strong activity of killing the protozoons like trichomonad and toxoplasma. The oligose is a indigestible sugar without any poisonous side effect on human body. The lacidophihin and oligose as micro-ecological regulator has remarkale "the effect of resting and benefiting".
STAXYN is available in 10 mg orally disintegrating tablets. STAXYN is not interchangeable with vardenafil 10 mg film-coated tablets (LEVITRA). STAXYN provides higher systemic exposure compared to vardenafil 10 mg film-coated tablets (LEVITRA). [See Clinical Pharmacology (12.3).]

STAXYN should be taken orally, as needed, approximately 60 minutes before sexual activity. The maximum dosing frequency is one STAXYN tablet per day. Sexual stimulation is required for a response to treatment. 

STAXYN should be placed on the tongue where it will disintegrate. The tablet should be taken without liquid. It should be taken immediately upon removal from the blister.

Those patients who require a lower or higher dose of vardenafil need to be prescribed vardenafil film-coated tablets [see Patient Counseling Information (17.11)].
Patches for application to the skin have a polymeric matrix containing at least one cosmetically active material and, embedd in the matrix, permanently orientated magnetic particles. A patch (1) is shown in the drawing in which the polymeric matrix (3) has magnetic particles (4) embedded in it, and one surface of the patch (5) is adhesive or becomes adhesive, such as on hydration. The magnetic particles are preferably ferrites, optional coated with a polyurethane, epoxy, polyester, polyamide or cyanoacrylate, and these are magnetized in situ once the patch has be prepared. The particles preferably comprise 0.2-80 %, especially 2-15 % of the volume of the matrix. The orientation of the magn field generated by the particles is preferably from one side of the patch to the other. The cosmetically active material that is also within the matrix may be a slimming agent, cleanser, anti-oxidant, anti-free radical agent, hydrating agent, depigmenting agent, liporegulator, anti-acne agent, anti- seborrheic, anti-aging agent, softener, anti-wrinkle agent, keratolytic agent, anti-inflammatory, refreshing agent, cicatrizing agent, vascular protector, antibacterial, antifungal, antiperspirant, deodorant skin conditioner, insensitizer, immunomodulator, nourisher, or humidity absorbent. In addition the matrix may contain a wide ran of other materials, such as enzymes, antibiotics, sugars, urea, hydroxylated polyacids, vitamins, oils, steroids, etc. The patch are prepared by dispersing the active material and magnetic particles in the matrix material, and, after (partial) polymerizatio passing this through a magnetic field so as to orientate the particles permanently.
A medical imaging system capable of acquiring image using a remotely accessible medical imaging device infrastructure. The medical imaging system includes an imaging client communicably coupled to an image acquisition unit. The imaging client is configured to transmit image data of an object acquired using the image acquisition unit, wherein the image data is acquired based on an imaging procedure. Imaging servers hosting medical imaging device infrastructures are communicably coupled to the imaging client. The imaging servers are configured to allocate a medical imaging device from the medical imaging device infrastructures to the imaging client based on the imaging procedure; process the image data received from the imaging client in the medical imaging device to generate images; and send the images to the imaging client. The imaging client is further configured to render the images of the object.
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.